Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07055893 | Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen | PHASE3 | NOT YET_RECRUITING | 390 | — | — | Mar 1, 2026 | Jan 30, 2027 | Jul 9, 2025 | 1 | Pakistan |
| Arm | Type | Description |
|---|---|---|
| Sinovac rabies vaccine | EXPERIMENTAL | Participants will be randomly assigned to receive Sinovac rabies vaccine. |
| Sanofi Pasteur Verorab® | ACTIVE_COMPARATOR | Participants will be randomly assigned to receive the marketed rabies vaccine Verorab® |
| Name | Type | Description |
|---|---|---|
| Rabies vaccine | BIOLOGICAL | Receiving five doses of rabies vaccine manufactured by Sinovac using the "Essen" PEP schedule |
| Verorab® | BIOLOGICAL | Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the "Essen" PEP schedule |
Inclusion Criteria: 1. Populations aged ≥1 years old; 2. Participants and/or participants' parents/legal guardians are able to understand and sign the informed consent form (ICF) voluntarily; 3. Participants are able to comply with the study procedures based on the investigator's assessment; 4. In ...